A total of 1045 consecutive patients presented to Peking University Cancer Hospital from August 1, 2008 to December 31, 2018 for SCLC therapies were enrolled retrospectively in this study. The inclusion criteria were histologically or cytologically‐confirmed small cell lung cancer patients, who were newly diagnosed without prior treatment. Patients who received only surgery or radiotherapy were excluded. Among this cohort, 988 patients who received at least one line of systemic chemotherapy and had a record of efficacy for measurable lesions (according to RECIST) were included for further analysis.

Electronic medical records were used to obtain demographic, clinical variables and medications as follows: age, gender, stage (The Veterans Administration Lung Study Group [VALSG]), Eastern Cooperative Oncology Group (ECOG) performance status, sites of metastases, systemic therapy treatments, local therapies, efficacy, most recent follow‐up, and death. Mortality data were obtained from the electronic medical records of the Follow‐up System of Beijing Cancer Prevention and Research Institute. The construction of the database was conducted by an independent researcher who was not involved in the care of patients.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.